openPR Logo
Press release

Irritable Bowel Syndrome Treatment Industry: Mapping Advances in Gastrointestinal Health (2023-2033)

Irritable Bowel Syndrome Treatment Industry: Mapping Advances

The global irritable bowel syndrome treatment market is expected to grow at a CAGR of 8.3%, reaching a valuation of US$ 8.3 billion by the end of 2033, from its current level of global sales of US$ 3.4 billion in 2022.

The irritable bowel syndrome (IBS) treatment market is focused on addressing the challenges of gastrointestinal disorders and presents significant market opportunities in the next decade. IBS is a chronic condition characterized by abdominal pain, bloating, and changes in bowel habits. The market for IBS treatment encompasses various therapeutic approaches aimed at managing symptoms and improving the quality of life for individuals affected by this debilitating condition.

Request the sample copy of report @ https://www.persistencemarketresearch.com/samples/9938

The treatment landscape for IBS has witnessed advancements in recent years, offering a range of options to alleviate symptoms and improve patients' well-being. From dietary modifications and lifestyle changes to pharmacological interventions and psychological therapies, the market caters to the diverse needs of individuals with IBS. These treatments aim to reduce pain, regulate bowel movements, and address the underlying factors contributing to the disorder.

The market opportunities in the IBS treatment market are driven by several factors. The increasing prevalence of IBS globally, coupled with a growing awareness of gastrointestinal health, has created a demand for effective treatment options. Additionally, the impact of IBS on patients' quality of life and the associated economic burden drive the need for innovative solutions. The market expansion is further fueled by the development of novel therapeutics and targeted approaches tailored to specific subtypes of IBS.

Looking ahead, the future of the IBS treatment market holds significant potential. Ongoing research efforts focus on understanding the underlying mechanisms of IBS, identifying biomarkers, and exploring personalized medicine approaches. Collaboration between healthcare providers, researchers, and industry stakeholders is crucial to drive innovation and improve the diagnosis and management of IBS. Furthermore, technological advancements and digital health solutions hold promise in enhancing patient engagement and providing more personalized treatment options.

For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/9938

In conclusion, the IBS treatment market plays a crucial role in addressing gastrointestinal disorders and improving the quality of life for individuals with IBS. The market opportunities in the next decade are driven by the increasing prevalence of IBS, growing awareness of gastrointestinal health, and advancements in treatment options. It is vital for healthcare professionals, industry leaders, and policymakers to collaborate and invest in this market, driving innovation and ensuring that individuals with IBS have access to effective and personalized treatment solutions.

Companies Covered in This Report -

• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Abbott Laboratories
• Novartis AG
• AstraZeneca PLC
• Ironwood Pharmaceuticals Inc. and Allergan Plc
• Bausch Health Companies Inc.
• GlaxoSmithKline, Plc.
• Lexicon Pharmaceuticals, Inc.
• Sucampo Pharmaceuticals, Inc..

Request For Report Customization @ https://www.persistencemarketresearch.com/request-customization/9938

Key Segments Covered in Irritable Bowel Syndrome Treatment Industry Research

By Product:

• Fiber Supplements
• Anti-Diarrheal
• Anticholinergic and Antispasmodic
• Antidepressant
• Antibiotics
• Alosetron
• Lubiprostone
• Linaclotide
• NHE3

By Indication:

• Irritable Bowel Syndrome with Constipation
• Irritable Bowel Syndrome with Diarrhoea
• Irritable Bowel Syndrome with alternating Constipation and Diarrhoea

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies and Stores
• Hypermarkets and Supermarkets

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

About us:
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Irritable Bowel Syndrome Treatment Industry: Mapping Advances in Gastrointestinal Health (2023-2033) here

News-ID: 3162095 • Views:

More Releases from Persistence Market Research

Blood Collection Tubes Market Size, Growth, Share & Trends 2025-2032 | Global Industry Forecast & Analysis
Blood Collection Tubes Market Size, Growth, Share & Trends 2025-2032 | Global In …
The blood collection tubes market plays a pivotal role in modern healthcare by enabling safe, efficient, and accurate collection, storage, and transportation of blood samples. Extensively used in diagnostic laboratories, hospitals, and research centers, these tubes are critical for hematology, biochemistry, immunology, and molecular testing. They help maintain sample integrity, minimize contamination risks, and streamline laboratory workflows, making them indispensable in clinical diagnostics. Request a Sample: https://www.persistencemarketresearch.com/samples/35126 Market Overview According to a recent study
Frozen Pastries Market to Reach $3.8 Bn by 2032 Driven by Convenience and Ready-to-Eat Demand
Frozen Pastries Market to Reach $3.8 Bn by 2032 Driven by Convenience and Ready- …
The global frozen pastries market is set for consistent expansion over the next decade, driven by the growing demand for convenient, ready-to-bake bakery products and evolving consumer lifestyles. According to market projections, the global frozen pastries market size is likely to be valued at US$ 2.6 billion in 2025 and is estimated to reach US$ 3.8 billion by 2032, growing at a CAGR of 5.7% during the forecast period from
Cookies Market to Reach US$ 54.4 Bn by 2032 Driven by Rising Demand for Premium Snacks
Cookies Market to Reach US$ 54.4 Bn by 2032 Driven by Rising Demand for Premium …
The global cookies market is witnessing steady growth, with its valuation expected to reach US$ 38.3 billion in 2025. According to projections, the market is set to rise significantly and reach approximately US$ 54.4 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.1% between 2025 and 2032. This growth trajectory is fueled by evolving consumer lifestyles, increasing demand for convenient and on-the-go snacks, and the rising
Flaxseeds Market Growth Driven by Health Trends | Valued at US$ 1,284.7 Mn in 2025
Flaxseeds Market Growth Driven by Health Trends | Valued at US$ 1,284.7 Mn in 20 …
The global flaxseeds market is witnessing substantial expansion, driven by the growing consumer awareness of health benefits associated with flaxseed consumption and its increasing use across diverse industries such as food and beverages, pharmaceuticals, and cosmetics. According to recent industry analysis, the global flaxseeds market size is likely to be valued at US$ 1,284.7 million in 2025, and is projected to reach US$ 2,145.3 million by 2032, expanding at a

All 5 Releases


More Releases for IBS

Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs. 👉 Download our latest market insights:
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide. A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011. The new bulkers, each with a capacity of 176,000 dwt, will be equipped